The introduction of thrombolytic therapy for stroke should be made according to a research protocol in order to solve the above mentioned uncertainties and to analyze the contextual factors which may influence its efficacy/effectiveness. Thrombolytics may be introduced in those centres which have the facilities, staff and technical equipment to enable the early assessment of these patients, within an accurate evaluation of its effects and the potential complications.
In order to reduce the therapeutic delay, which determines thepotential effectiveness of the recanalization or neuroprotectivetherapies, measures promoting the identification, transportationand assessment of the patients in the shortest
time possible should be promoted. In this sense, the role that the called "stroke units" may have at hospital level should be considered.
There are no data in our context regarding the patients' preferences in front of these type of therapies which mean a short term risk and a long term benefit, in case the patient survives, of minor or no impairment. In order for patients to be able to show their preferences (short term risk versus later benefit) objective adequate information should be provided. Research in this field should be promoted in our country. Research regarding the epidemiological aspects of cerebral vascular disease in our context should be also promoted, as regards the incidence and prevalence of the disease, the impairment it causes and its socio-economic impact.